Skip to main content
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Research Article

High serum carbohydrate antigen 125 concentration can predict serous effusion but not gastrointestinal malignancy in male patients

verfasst von: Xian Zhu, Wei Zhou, Yan Chen, Jun Gao, Fanyang Kong, Jie Liu, Zhaoshen Li, Jun Gao, Yu Bai

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aims to evaluate the diagnostic accuracy of carbohydrate antigen 125 (CA125) in male patients for predicting gastrointestinal malignant diseases. One hundred twenty consecutive male patients underwent CA125 test after admission to the Department of Gastroenterology in Changhai Hospital, the Second Military Medical University, from April to June 2013. Data of age, main symptoms, and final diagnosis were summarized. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of CA125 for malignancy were estimated, and the receiver operating characteristic (ROC) analysis and the area under the curve (AUC) were also performed to evaluate the diagnostic value of CA125 in male patients. The PPV, NPV, PLR, and NLR of CA125 in malignancy were 55 %, 69 %, 1.90, and 0.71, respectively. However, we found that an elevated serum CA125 level was more common in male patients with serous effusion than those with malignancy. The PPV, NPV, PLR, and NLR of CA125 in serous effusion were 85 %, 96 %, 12.70, and 0.09, respectively. In the ROC analysis, the AUC values for CA125 was 0.96 (95 % confidence interval, 0.93–0.99) for discriminating patients with serous cavity effusion from those without serous effusion. CA125 has a higher accuracy in detecting serous effusion than malignancy in male patients with gastrointestinal diseases. It is of little significance for male patients to perform CA125 test for malignancy.
Literatur
1.
Zurück zum Zitat Bast RJ, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.PubMedCentralCrossRefPubMed Bast RJ, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010;7:335–9.CrossRefPubMed Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010;7:335–9.CrossRefPubMed
3.
Zurück zum Zitat Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod. 2000;15:1261–5.CrossRefPubMed Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod. 2000;15:1261–5.CrossRefPubMed
4.
Zurück zum Zitat Kabawat SE, Bast RJ, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–85.CrossRefPubMed Kabawat SE, Bast RJ, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–85.CrossRefPubMed
5.
Zurück zum Zitat Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, et al. Ovarian cancer, version 3.2012. J Natl Compr Cancer Netw. 2012;10:1339–49. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, et al. Ovarian cancer, version 3.2012. J Natl Compr Cancer Netw. 2012;10:1339–49.
6.
Zurück zum Zitat Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem. 2011;48:295–9.CrossRefPubMed Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem. 2011;48:295–9.CrossRefPubMed
7.
Zurück zum Zitat Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007;8:1054–5.CrossRefPubMed Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007;8:1054–5.CrossRefPubMed
8.
Zurück zum Zitat Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43:1755–63.PubMedCentralCrossRefPubMed Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43:1755–63.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Cartei G, Cartei F, Bertin M, Padoan A, Zustovich F, Nicoletto MO, et al. CA125 reference values change in male and postmenopausal female subjects. Clin Chem Lab Med. 2013;51:413–9.CrossRefPubMed Cartei G, Cartei F, Bertin M, Padoan A, Zustovich F, Nicoletto MO, et al. CA125 reference values change in male and postmenopausal female subjects. Clin Chem Lab Med. 2013;51:413–9.CrossRefPubMed
10.
Zurück zum Zitat Light RW, Macgregor MI, Luchsinger PC, Ball WJ. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–13.CrossRefPubMed Light RW, Macgregor MI, Luchsinger PC, Ball WJ. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–13.CrossRefPubMed
11.
Zurück zum Zitat Bai Y, Xu C, Zou DW, Gao J, Li ZS. Diagnostic accuracy of features predicting lower gastrointestinal malignancy: a colonoscopy database review of 10,603 Chinese patients. Colorectal Dis. 2011;13:658–62.CrossRefPubMed Bai Y, Xu C, Zou DW, Gao J, Li ZS. Diagnostic accuracy of features predicting lower gastrointestinal malignancy: a colonoscopy database review of 10,603 Chinese patients. Colorectal Dis. 2011;13:658–62.CrossRefPubMed
12.
Zurück zum Zitat Bai Y, Li ZS, Zou DW, Wu RP, Yao YZ, Jin ZD, et al. Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patients from 1996 to 2006. Gut. 2010;59:722–8.CrossRefPubMed Bai Y, Li ZS, Zou DW, Wu RP, Yao YZ, Jin ZD, et al. Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patients from 1996 to 2006. Gut. 2010;59:722–8.CrossRefPubMed
13.
Zurück zum Zitat Bast RCJ, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed Bast RCJ, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed
14.
Zurück zum Zitat Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–303.CrossRefPubMed Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–303.CrossRefPubMed
15.
Zurück zum Zitat He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.PubMedCentralCrossRefPubMed He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154–61.CrossRefPubMed Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154–61.CrossRefPubMed
17.
Zurück zum Zitat Sari R, Yildirim B, Sevinc A, Hilmioglu F. Re. Zuckerman et al.—Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am J Gastroenterol. 2001;96:253–4.PubMed Sari R, Yildirim B, Sevinc A, Hilmioglu F. Re. Zuckerman et al.—Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am J Gastroenterol. 2001;96:253–4.PubMed
18.
Zurück zum Zitat Sevinc A, Buyukberber S, Sari R. Elevated serum CA-125 levels: hepatitis or ascites? Gynecol Oncol. 2000;76:141–2.CrossRefPubMed Sevinc A, Buyukberber S, Sari R. Elevated serum CA-125 levels: hepatitis or ascites? Gynecol Oncol. 2000;76:141–2.CrossRefPubMed
19.
Zurück zum Zitat Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.CrossRefPubMed Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254–7.CrossRefPubMed
20.
Zurück zum Zitat Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M. Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res. 2000;20:1201–3.PubMed Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M. Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res. 2000;20:1201–3.PubMed
21.
Zurück zum Zitat Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10:150–4.CrossRefPubMed Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10:150–4.CrossRefPubMed
22.
Zurück zum Zitat Yilmaz MB, Nikolaou M, Cohen SA. Tumour biomarkers in heart failure: is there a role for CA-125? Eur J Heart Fail. 2011;13:579–83.CrossRefPubMed Yilmaz MB, Nikolaou M, Cohen SA. Tumour biomarkers in heart failure: is there a role for CA-125? Eur J Heart Fail. 2011;13:579–83.CrossRefPubMed
23.
Zurück zum Zitat Huang F, Zhang K, Chen J, Cai Q, Liu X, Wang T, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem. 2013;46:1694–700.CrossRefPubMed Huang F, Zhang K, Chen J, Cai Q, Liu X, Wang T, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem. 2013;46:1694–700.CrossRefPubMed
Metadaten
Titel
High serum carbohydrate antigen 125 concentration can predict serous effusion but not gastrointestinal malignancy in male patients
verfasst von
Xian Zhu
Wei Zhou
Yan Chen
Jun Gao
Fanyang Kong
Jie Liu
Zhaoshen Li
Jun Gao
Yu Bai
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1625-6

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.